Introduction
============

Repetitive DNA sequences with a capacity to expand (sometimes up to hundreds or thousands of repeats) are found in the human genome in non-coding and exonic regions. They are currently known to be associated with approximately 40 human diseases (reviewed in [@B33]). Trinucleotide repeats were the first to be identified, but an intensive search over the last decades has shown tetra-, penta- and hexanucleotide repeats also expanding above a normal polymorphic range in some human subjects ([@B33]). Most of the repeat-associated disorders manifest with neurological, neuropsychiatric or neuromuscular symptoms. Among them are the spinocerebellar ataxias (SCA1, DRPLA, SCA2, MJD/SCA3, SCA6, SCA7, SCA8, SCA10, SCA12, SCA17, SCA31, and SCA36), Huntington's disease, myotonic dystrophy, spinal-bulbar muscular atrophy and fragile X syndrome. While each of these diseases is rare worldwide, together they are one of the commonest causes of hereditary neurological pathology ([@B37]; [@B33]).

Non-human primates have short repeat alleles at all these *loci* ([@B2]), which implies that expansion into pathogenic ranges occurred after Homo-Pan split. If we are able to identify the genetic backgrounds where *de novo* expansions occurred (place-of-birth for these mutations), many new possibilities will open for the study of mutational origins and spread ([@B37]; [@B31]; [@B15]; [@B3]; [@B14]), as well as mechanisms of repeat instability ([@B23]; [@B8]; [@B42]; [@B35]) and genetic modifiers for these diseases ([@B10]; [@B16]; [@B4]).

To characterize the genetic background of expanded alleles, polymorphic markers are crucial given their capacity to distinguish alleles identical-by-state. Single nucleotide polymorphisms (SNPs) are the most common source of genetic variation in the human genome, but their biallelic nature reduces their informativeness. Short tandem repeats (STRs) have a very high polymorphism information content (PIC), but their mutation rate ranging 10^-6^--10^-2^ *per* locus *per* generation ([@B9]) causes a high rate of recurrence. A combined stepwise analysis with both SNPs and STRs may then be the key to overcome both problems.

In Machado-Joseph disease (MJD/SCA3), SNPs and STRs have been used mainly to study genetic epidemiology in this dominant ataxia, the most frequent SCA worldwide ([@B25]); however, there is also evidence on the importance of extending haplotype analyses to study MJD instability ([@B24]). MJD is caused by an expanded (CAG)~n~ in exon 10 of the *ATXN3* gene (14q32.12) ([@B13]). As in other SCAs, repeat instability of mutated/expanded alleles has received enormous attention, due to its importance in the clinical phenomenon of anticipation: the earlier age-at-onset (AO) and more severe symptoms in successive generations, as the repeat number tends to increase upon transmission to offspring, and repeat size correlates inversely with AO. Despite its importance, instability is not yet fully understood in MJD or other repeat-associated disorders; only a few modifiers have been identified ([@B28]). In MJD, in addition to the length of the initial repeat tract and the gender and age of the transmitting parent ([@B19]; [@B27]; [@B39]), SNP rs12895357 near the CAG repeat has been shown to affect repeat instability, the genotype (CAG)~exp~-C/(CAG)~normal~-G of the transmitting parent being associated with increased instability ([@B12]; [@B20]; [@B24]).

Given the importance of haplotype analyses (including SNPs and STRs) to perform a comprehensive study of oligonucleotide repeat-related diseases, we designed a strategy to identify disease-associated haplotypes and show here the example of this approach to analyse the *ATXN3* locus.

Materials and Methods
=====================

Samples
-------

We optimized a protocol with DNA samples extracted from saliva, buccal swab and peripheral blood through different techniques, by using the QIAamp^®^ DNA Blood Mini kit, the Citogen^®^Blood kit, the Chelex100 chelating resin, as well as through the standard method of salting-out. We also tested some DNA samples stored for more than two decades at 4°C. This study was carried out with anonymized DNA samples available in our laboratory, in accordance with the recommendations of international guidelines. Previous written informed consent was obtained from all subjects to use their DNA samples for research purposes, in accordance with the Declaration of Helsinki. DNA quantification was performed with Nanodrop, to prepare aliquots with a final DNA concentration of 7.5 ng/μL.

Selection of Polymorphic Markers
--------------------------------

We selected a set of 26 SNPs within a region of 4 kb encompassing the (CAG)~n~, based on (1) minor allele frequencies (MAF \> 5%; Ensembl ^[1](#fn01){ref-type="fn"}^); (2) recombination hotspots (within the same haplotype block; The International Genome Sample Resource and The 1000 Genomes Project); and (3) sequence alignments of previously analyzed patients (to include SNPs that discriminate MJD lineages ([@B26]; [@B32]); [Supplementary Table S1](#SMT1){ref-type="supplementary-material"}).

To select STRs, we used the Tandem Repeats Finder tool^[2](#fn02){ref-type="fn"}^ and the following criteria for putative polymorphic repeats: consensus size of 2--5 bp; copy number above 7; matches above 80%; and proximity to the (CAG)~n~. This search was done within the human reference *ATXN3* and 250 kb up and downstream to it (NG_008198.2). Seven STRs were selected, based on their score (\>8.5): one tetra, two tri and four dinucleotide repeats, less than 223 kb from the (CAG)~n~, thus reducing the likelihood of recombination ([Table 1](#T1){ref-type="table"}). Three of these STRs (TAT223, AC21 and GT190) have been analyzed in previous haplotype studies in several MJD populations, which will be useful for future comparisons ([@B22]).

###### 

STRs selected for MJD haplotype analysis, respective distances from the (CAG)~n~ and primers used for genotyping. F - Forward primer; R - Reverse primer.

  Primers         Distance from the (CAG)~n~   Primer sequence (5′--3′)
  --------------- ---------------------------- ----------------------------
  TAT223_F^∗1^    223 kb                       CCACACTTCCTTTGGACCAT
  TAT223_R                                     GGTAGGCACCAGCTACTTGGG
  GT199_F         199 kb                       TTACTGGGTAGGATATACATTCC
  GT199_R^∗1^                                  CAGCCTTCCCCCGAGTCC
  ATA194_F        194 kb                       CCTTATCTAACCTCCTACATCTCAGC
  ATA194_R^∗2^                                 GCAGGGCAGGCAATGAAACACG
  MJD52_F                                      CCAGTGACTACTTTGATTCG
  CAG_R^∗3^                                    GTGTGAAGGTAGCGAACATGATG
  AC21_F^∗1^      21 kb                        CTTCAGCTCAAATGCTATCAAAC
  AC21_R                                       CAAGGATGGCTAGTGCAGAAAT
  AAAC123_F       123 kb                       CAGATGGGATAGGCCACAGT
  AAAC123_R^∗1^                                AGTGGAGGCTTCAACCTGTT
  GT190_F^∗4^     190 kb                       GAGGGGACCTGGCCTACTAC
  GT190_R                                      ACCTACAGTAACACACTTTGCAC
  AC190_F^∗2^     191 kb                       CTGGGAGGAGGAGGGTACAA
  AC190_R                                      AACCCTGACTCAACTCTCGG
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Primer Design
-------------

We used the online software Primer3Plus to design specific primers, to amplify and sequence previous selected polymorphic markers, in addition to the MJD_CAG repetitive region ([Table 2](#T2){ref-type="table"}). Next, the alignment tool BLAST was used to guarantee the specificity of the designed primers: at maximum three mismatches (or two at 3′ end) were allowed if homologous sequences were observed. Finally, the occurrence of hairpins and primer-dimers (including self-dimers) was tested with AutoDimer ([@B40]).

###### 

Primers designed to amplify and sequence a 4 kb flanking region of the *ATXN3*\_CAG repeat. F - Forward primer; R - Reverse primer.

  Name         Primer sequence (5′--3′)
  ------------ ----------------------------
  MJDcloF_F    CAATTATTGGCCTTTCTGAACC
  MJD52_F      CCAGTGACTACTTTGATTCG
  MJD653_R     GCAAATGAGTGTTGGTTTATAGACCC
  MJD716_F     ACAGAGTCTCGCTCTGTCGCCCAG
  MJD1260_R    GCTGTCTGAAACATTCAAAAGTGAAG
  MJD7a_R      TGCTCCTTAATCCAGGGAAATTTAG
  MJD1342_F    CCACCAGTTCAGGAGCACTT
  MJD1396_F    TCATGTTCGCTACCTTCACACT
  MJD2109_F    GAGTTACTTTCCAGGTCTCGG
  MJD2129_R    CCGAGACCTGGAAAGTAACTC
  MJD2552_F    GATCCAGCAGTCCCAATCATGTA
  MJD2646_R    TGCCTGGTCAGCTATAAGCA
  MJD2942_F    TGGACACGGTGGCTTACGCCT
  MJD3417_F    CTGGGCTGGGTGGCGGTGGCTCA
  MJD3936C_R   CTAAAGGTTTTTATCTTGCTAGAC
  MJDcloR_R    AGCCTTCTCTAACACCACCTTGG

SNP Haplotypes
--------------

Genotyping of the SNPs was done with amplification of three fragments, not including the CAG tract, which allowed equal amplification of normal and expanded alleles. Reactions were performed using the following primers, annealing conditions, extension time, and number of cycles: MJDcloF-MJD1260R (62°C for 90 s; 90 s; 33 cycles); MJD1342F-MJD2646R (59°C for 90 s; 120 s; 35 cycles); MJD2552F-MJDcloR (61°C for 90 s; 120 s; 35 cycles). Amplification reactions were done in a total volume of 10 μL, with 0.2 μM of each primer, 1x of Taq PCR Master Mix Kit Qiagen^®^, 0.5x of Q-Solution for Qiagen^®^, and 15 ng DNA.

Phase of SNPs on expanded chromosomes was assessed through (1) amplification of two fragments encompassing the CAG repeat and either up or downstream regions (which resulted in the overrepresentation of normal alleles) and (2) allele-specific amplification of rs7142326 (amplicon length of 1384 bp). Reactions were performed using the following primers, annealing conditions, extension time and cycles: MJDcloF_F-MJD7a_R (60°C for 90 s; 120 s; 35 cycles), MJD52_F-MJD2646_R (58°C for 90 s; 120 s; 20 cycles; plus, 57°C for 90 s; 120 s; 20 cycles) and MJD1342_F-MJD3936C_R (57°C for 90 s; 120 s; 40 cycles). PCRs included 0.2 μM of each primer, 1x of Taq PCR Master Mix Kit Qiagen^®^, 0.5x of Q-Solution for Qiagen^®^and 15 ng DNA, in a final volume of 10 μL.

To sequence the amplified fragments, we started by purification with thermosensitive Alkaline phosphatase: Exonuclease I, ExoFastAP (Thermo Scientific) (1:5) at 37°C for 15 min, followed by 15 min at 80°C to inactivate the enzyme. Sequence reactions were done with 0.5 μL BigDye^®^Terminator Cycle kit (Applied Biosystems), according to manufacturer's instructions.

A final purification of DNA was performed using a cross-linked dextran matrix (Illustra™ Sephadex™ G-50, GE Healthcare), with centrifugation for 4 min at 4400 rpm. After loading the sequencing product, the same conditions of centrifugation resulted in a deposit containing the final product, ran in an ABI PRISM 3130x/Genetic Analyzer (Applied Biosystems) with Hi-Di™ formamide.

STR Haplotypes
--------------

STRs were all amplified together with the CAG repeat, in a multiplex PCR reaction, in a final volume of 10 μL, using 0.25 μM (AAAC123, AC21, GT199, and GT190), 0.125 μM (TAT223, ATA194, and AC190), and 0.2 μM (CAG, and MJD52_F) of each primer, 1x of Taq PCR Master Mix Kit Qiagen^®^, 0.5x of Q-Solution for Qiagen^®^, and 7.5 ng DNA. The initial denaturation was performed at 95°C for 15 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 62°C for 90 s and extension at 72°C for 60 s; with a final extension at 70°C for 30 min. Analysis of fragment length was performed with ABI PRISM 3130x/Genetic Analyzer (Applied Biosystems). A mix of GeneScan™ 500 LIZ™ size standard (Thermo Scientific):Hi-Di™ formamide (Applied Biosystems) (1:20) was added to 2 μL of PCR product and run in matrix G5, analyzed with GeneMapper v4.0. Allelic phases associated with the expansion were assessed by segregation and bioinformatically, using PHASE v.2.1.1 whenever DNA samples from relatives were not available.

Protocol Design and Applications
================================

Analysis of the genetic background of expanded alleles at repetitive *loci* is important for a comprehensive study of repeat-associated neurological disorders. Most approaches, however, are rather *ad hoc* and lack a strategy to get the most from such valuable SNP and/or STR data from patients. Thus, we designed a pipeline to characterize the haplotype background of repetitive disease-associated *loci* that can be used to study any of these neurological disorders; a step-by-step protocol, optimized to assess genetic backgrounds of MJD patients, is here detailed as an example.

Process Overview
----------------

Our strategy focused first on the selection of SNPs to identify stable genetic backgrounds, defining lineages. Given the low mutation rate of SNPs (∼2.5 × 10^-8^), events on the origin of these polymorphic markers are considered unique during the evolution of a species ([@B30]). It is important that SNPs are selected within a distance to the pathogenic repeat small enough to lie within a single haplotype block, thus avoiding recombination to play a relevant role on the lineages identified. Next, analysis of STRs allows differentiating a high number of haplotypes inside each lineage. Fast-evolving STRs flanking the disease *locus* should have a high potential to be pure, simple stretches, in order to be reliable as molecular clocks. By following this two-level strategy (STRs analyzed within stable SNP lineages), it is possible to achieve a high discrimination power, not compromising the discrimination of haplotypes identical-by-state (not by-descent) ([Figure 1](#F1){ref-type="fig"}).

![Strategy followed to identify mutational origins in repeat-associated diseases by assessing SNP and STR haplotype backgrounds associated to expanded alleles.](fgene-10-00038-g001){#F1}

Protocol to Identify MJD Haplotype Backgrounds
----------------------------------------------

We applied the strategy described to optimize a protocol to assess disease-associated haplotypes in MJD. While sequence, frequency and population data are widely available for SNPs in databases such as Ensembl and The 1000 Genomes Project, the search for STRs must rely on the potential PIC that a repetitive sequence harbors, since there are not many data available regarding allele frequencies and repeat configuration of non-deleterious STRs. For this reason, we selected potential STRs from Tandem Repeat Finder and tested their heterozygosity value by genotyping a set of random samples. After confirming their high potential to discriminate alleles identical-by-state, we sequenced at least one allele size *per* STR from two major ethnic groups: Europeans and Asians. Further analyses included exclusively pure STRs (or STRs with regular repeat configurations), without any additional source of size variation (such as indels or other tandem repeats) within the amplicon that includes the STR of interest. While optimizing the protocol, we performed three standard PCRs, to obtain SNP genotypes of MJD patients; followed by two PCRs encompassing the (CAG)~n~ ([Figure 2A](#F2){ref-type="fig"}) and an allele-specific PCR ([Figure 2B](#F2){ref-type="fig"}), to assess alleles that segregated with the MJD expansion. This way, even in families with a single DNA sample available from the proband, we were able to infer directly alleles in *cis* with the expansion (i.e., lineages). For genotyping of STRs, we optimized a single multiplex reaction, to amplify all 7 STRs and the MJD_CAG repeat together ([Figure 3](#F3){ref-type="fig"}), this way reducing quantity of DNA, time, reagents and sample's manipulation.

![Electropherograms showing **(A)** SNP rs7153374 genotyped by a standard PCR *versus* (CAG)~n~-biased PCR and **(B)** SNP rs8004149 genotyped by a standard PCR *versus* allele-specific PCR.](fgene-10-00038-g002){#F2}

![Electropherograms showing amplified products from the optimized multiplex PCR for the analysis of the CAG repeat of *ATXN3* and seven flanking STRs.](fgene-10-00038-g003){#F3}

We validated our pipeline for MJD haplotyping by testing the optimized protocol in a randomly selected subset of 100 MJD families from our large cohort. Genotypes of SNPs and STRs were obtained in 92 families, a successful rate for SNP and STR amplification of 92% - taking into account the long-term storage of most DNA samples analyzed (most for over two decades), we considered 8% a low failure rate. We have also estimated success rate for haplotype inference, given the importance of assessing allelic phase of polymorphisms segregating with the pathogenic expansion: following our strategy of SNP allele-specific amplification, MJD lineages were accurately identified in all 92 families; as for flanking STRs, we were able to reconstruct haplotypes in 85% of the families genotyped (78/92); of note is the fact that 48% (44/92) of the families were composed solely by the proband and that in other 15% (14/92) only a single relative was available. Therefore, we may conclude that, following this protocol, complete extended haplotypes (SNPs-STRs) can be inferred in a larger number of MJD families, even in very small families or isolated patients.

Usefulness and Perspectives of Application
------------------------------------------

1.  **Genetic epidemiology.** Geographical differences in disease prevalence may be explained by haplotype studies, as shown for Huntington disease (HD), with the highest risk HD haplogroups being found in Europe, while absent in East Asia ([@B43]). In MJD two *de novo* expansions seem to have occurred, and, so far, its presence in remote and ethnically diverse populations has been explained by genetic drift and founder effects ([@B11]; [@B22], [@B26]; [@B32]); This optimized protocol could clarify remaining questions about the origins and history of MJD mutations. By following the same pipeline to study other expanding *loci*, one could understand better disease prevalence and provide a clearer scenario about the occurrence of *de novo* expansions ([@B41]).

2.  **Mechanisms of *de novo* expansion.** Analysis of SNPs and STRs flanking *ATXN3* suggested a multistep mutation mechanism for the evolution of the CAG repeat responsible for MJD ([@B23]). Also based on the analysis of flanking haplotypes, other authors explained the origin of a rare intermediate MJD allele (45 CAGs) after a gene conversion event ([@B29]). In other expansion diseases, risk SNP haplotypes seem to predispose to large jumps, namely large expansions into the pathogenic range in *HTT* (responsible for HD) ([@B42]) and in *C9orf72* (the most common known genetic cause of amyotrophic lateral sclerosis and frontotemporal lobar degeneration) ([@B44]) or large contractions into the normal range in fragile X ([@B21]).

3.  **Instability of expanded alleles.** Once expanded, the haplotype background seems to affect (CAG)~n~ intergenerational instability, since *cis*-elements in different haplotypes may regulate instability at that *locus.* In paternal transmission of MJD, opposite biases towards further expansion or contraction have been observed on specific SNP backgrounds: TTACAC *versus* GTGGCA haplotypes ([@B24]); this shows the relevance of further exploring the effect of flanking sequences on repeat instability. Haplotypes can serve as tags of *cis* or *trans* elements influencing *de novo* expansion or biasing towards further expansion or contraction, but can also have a direct effect. In the SCA7 gene, CTCF binding-sites *cis* to the expansion were shown to regulate *ATXN7*\_CAG hyperinstability ([@B17], [@B16]). Also, a haplotype study in fragile X has shown the direct influence of a flanking SNP on the replication of CGG repeats, due to its location within a medium reiterative element 1B sequence, proved to affect chromatin structure ([@B6]). Through the identification of haplotypes, either with direct or indirect effect on repeat instability, we can improve genetic counseling, by predicting further expansion or contraction in offspring, but also understand better the mechanisms behind such events.

4.  **Phenotype modifiers.** Expanded repeat disorders frequently show an inverse correlation between expansion size and AO; however, this correlation explains only part of AO variation ([@B5]). Haplotype background may play a direct role in disease expressivity; even after correcting for the known effect of expansion size; this is the case when a given SNP lies in the promoter or regulatory sequences of repeat-associated *loci*, which can affect binding of transcription factors, thus altering gene expression and disease presentation. In HD, SNP rs13102260 was identified as a modifier of AO. This SNP is located in a NF-κB binding site that regulates *HTT* promoter transcriptional activity. *In vitro* data showed a direct effect of rs13102260 on NF-κB binding and huntingtin expression, this way affecting disease presentation ([@B4]).

5.  **Clinical laboratory diagnosis.** The analysis of polymorphisms flanking the disease-causing repeat may also be helpful in diagnosis. A new genetic tool using 13 STRs flanking the expansion repeat has been proposed to help fragile X detection, avoiding ambiguity due to allele dropout ([@B34]). Analysis of genetic markers is also important for predictive testing, namely to solve cases of apparent homoallelism, i.e., when a single peak may represent two normal alleles of the same size or a second allele expanded beyond the range of detection of the assay ([@B18]; [@B38]).

6.  **Allele-specific therapies.** The urgency to develop direct therapies to prevent or slow progression of neurodegeneration led some authors to propose the sub-expression of the causative gene as a potential approach ([@B7]). In the case of *ataxin-3*, however, depletion of the gene results in cell death, by accumulation of ubiquitinated material, cytoskeletal disorganization and loss of cell adhesion ([@B1]). Therefore, the development of small interfering RNAs, based on the presence of a SNP that discriminates between wild-type and mutant transcripts, could be an efficient strategy for treatment of MJD. There are several SNPs described flanking the *ATXN3*\_CAG repeat; however, for allele-specific therapy, patients must be heterozygous for the target SNP. The protocol optimized here for MJD may be used to identify the most informative SNPs for each population; the same pipeline can be followed to perform similar analysis in other repeat-associated diseases.

Conclusion
==========

Identification of mutational haplotype backgrounds is key to unravel the mechanisms behind repeat-associated diseases. The strategy proposed was based on the analysis of fast evolving STR markers, placed within stable SNP-based lineages. By using the example of MJD, we have shown the procedure to assess allelic phases of both SNPs and STRs segregating with expanded alleles. Haplotype definition is crucial in dominant diseases, since normal alleles are not on the mutational background where *de novo* expansion(s) took place but are inherited from the non-affected parent. This is also relevant for recessive diseases, since two mutations (expanded alleles) in homozygosity may not share a common ancestral origin. When the gene of interest is on the X chromosome, that allows to infer haplotypes directly in males (e.g., when analyzing the CAG expansion in the *androgen receptor*, responsible for SBMA) ([@B36]).
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